Carmot Therapeutics is a U.S.-based biotech company focused on developing incretin-based therapies, including CT-388 (a weekly injectable dual GLP-1/GIP agonist), an oral small-molecule GLP-1 agonist (CT-996), and another injectable GLP-1/GIP candidate (CT-868)
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC
But scheduling a short walk in the evening or investing in a standing desk for your post-lunch work sessions can help you avoid GLP-1 nausea
Rotating among these sites with each injection helps prevent lipodystrophychanges in subcutaneous fat tissue that can affect medication absorption
The challenge is that many people find themselves gaining weight after they stop taking them, sometimes called the Ozempic Rebound
Whether you have health insurance through your employer or buy it on the marketplace, there's a good chance you'll see some changes to your plan in 2026